These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18491480

  • 1. Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 3: Clinical management.
    Kil EH, Heymann WR, Weinberg JM.
    Cutis; 2008 Apr; 81(4):327-35. PubMed ID: 18491480
    [Abstract] [Full Text] [Related]

  • 2. Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 4: Additional therapeutic considerations.
    Kil EH, Heymann WR, Weinberg JM.
    Cutis; 2008 Apr; 81(4):343-7. PubMed ID: 18491483
    [Abstract] [Full Text] [Related]

  • 3. Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 1: Epidemiology.
    Kil EH, Heymann WR, Weinberg JM.
    Cutis; 2008 Mar; 81(3):227-33. PubMed ID: 18441845
    [Abstract] [Full Text] [Related]

  • 4. Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 2: Pathogenesis and cutaneous manifestations.
    Kil EH, Heymann WR, Weinberg JM.
    Cutis; 2008 Mar; 81(3):247-54. PubMed ID: 18441848
    [Abstract] [Full Text] [Related]

  • 5. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
    Lawrence KR, Golik MV, Davidson L.
    Am J Ther; 2009 Mar; 16(4):333-8. PubMed ID: 19617720
    [Abstract] [Full Text] [Related]

  • 6. Re: Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections.
    Khawcharoenporn T.
    J Am Board Fam Med; 2011 Mar; 24(3):331; author reply 332-3. PubMed ID: 21551408
    [No Abstract] [Full Text] [Related]

  • 7. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections.
    Frei CR, Miller ML, Lewis JS, Lawson KA, Hunter JM, Oramasionwu CU, Talbert RL.
    J Am Board Fam Med; 2010 Mar; 23(6):714-9. PubMed ID: 21057066
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial agents in treatment of MRSA infections.
    Johnson MD, Decker CF.
    Dis Mon; 2008 Dec; 54(12):793-800. PubMed ID: 18996282
    [No Abstract] [Full Text] [Related]

  • 9. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE, Wells EM.
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [Abstract] [Full Text] [Related]

  • 10. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
    Loffler CA, Macdougall C.
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081
    [Abstract] [Full Text] [Related]

  • 11. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM, Weigelt J, Li JZ, Duttagupta S.
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [Abstract] [Full Text] [Related]

  • 12. Multi-systemic methicillin resistant Staphylococcus aureus (MRSA) community-acquired infection.
    Michalopoulos A, Falagas ME.
    Med Sci Monit; 2006 May; 12(5):CS39-43. PubMed ID: 16641881
    [Abstract] [Full Text] [Related]

  • 13. Antibiotic options for treating community-acquired MRSA.
    Powell JP, Wenzel RP.
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
    [Abstract] [Full Text] [Related]

  • 14. An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus.
    Arnold FW, Wojda B.
    J Ky Med Assoc; 2005 May; 103(5):206-10. PubMed ID: 15918650
    [Abstract] [Full Text] [Related]

  • 15. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
    Hyun DY, Mason EO, Forbes A, Kaplan SL.
    Pediatr Infect Dis J; 2009 Jan; 28(1):57-9. PubMed ID: 19057459
    [Abstract] [Full Text] [Related]

  • 16. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
    Stryjewski ME, Chambers HF.
    Clin Infect Dis; 2008 Jun 01; 46 Suppl 5():S368-77. PubMed ID: 18462092
    [Abstract] [Full Text] [Related]

  • 17. Management of cutaneous lesions associated with an emerging epidemic: community-acquired methicillin-resistant Staphylococcus aureus skin infections.
    Cohen PR, Grossman ME.
    J Am Acad Dermatol; 2004 Jul 01; 51(1):132-5. PubMed ID: 15243539
    [No Abstract] [Full Text] [Related]

  • 18. Management of methicillin-resistant Staphylococcus aureus (MRSA) skin infections and MRSA colonization.
    Terushkin V, Brownell I.
    J Drugs Dermatol; 2008 Jun 01; 7(6):597-601. PubMed ID: 18561595
    [No Abstract] [Full Text] [Related]

  • 19. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.
    Marcinak JF, Frank AL.
    Expert Rev Anti Infect Ther; 2006 Feb 01; 4(1):91-100. PubMed ID: 16441212
    [Abstract] [Full Text] [Related]

  • 20. Update on the characterization of Staphylococcus aureus skin infections in a pediatric dermatology tertiary health care outpatient facility: antibiotic susceptibility patterns and decreased methicillin resistance.
    Diamantis ML, Ortega-Loayza AG, Morrell DS.
    J Am Acad Dermatol; 2011 Feb 01; 64(2):440-1. PubMed ID: 21238834
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.